Quantcast
  • E-mail
  • Print
  • Comment
  • Font Size
  • Digg
  • del.icio.us
  • Discuss article

Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumour Cells

Posted on: Thursday, 17 June 2004, 06:00 CDT

We have described a novel approach to cancer treatment that is based on the unique feature of invasive bacteria such as S. typhimurium to infect non-phagocytic cells. In fact we have shown that tumour cells are easily infected by invasive derivatives of S. typhimurium, through the expression of the type three secretion system. Infected tumour cells are not directly killed by S. Typhimurium. Rather, Salmonella-infected tumour cells upregulate the expression of MHC I molecules, present determinants of bacterial origin and become targets of anti-Salmonella specific T cells. Moreover, intratumoural injection of Salmonella facilitates the recruitment of immune cells into the infected tumour area, possibly explaining the intrinsic anticancer property reported in literature. In order to fully appreciate the anticancer therapeutic properties of invasive S. typhimurium, we expanded anti-Salmonella specific T cells through systemic vaccination just before topical bacterial application. In fact, we show here that the combination of intratumoural injection of invasive Salmonella with DC-based anti- Salmonella specific vaccination results in complete tumour regression in 60% of treated mice, whereas simple intratumoural bacterial injection leads to maximum 20% of survival. Furthermore, we have shown protective immunity to subsequent tumour challenge in nearly 80% of survived mice indicating the generation of specific responses to endogenously expressed tumour antigens. In conclusion, our combinatorial immuno-therapeutical approach helps overcome immune escape mechanisms adopted by tumour cells because it is independent on the kinetic of expression of tumour antigens and because it avoids ignorance of the tumour site.

F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, M.P. Colombo, G. Dougan, M. Rescigno

European Institute of Oncology (IEO), Milan, Italy

Copyright Edizioni Minerva Medica Mar 2004

More News in this Category


Related Articles



Rating: 3.3 / 5 (3 votes)
Rate this article:
1/52/53/54/55/5

User Comments (0)

Comment on this article

Your Name
Text from the image
Comment
max 1200 chars
* All fields are required